NasdaqGS:REGNBiotechs
How Cemdisiran’s Phase 3 Success at Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story
Regeneron Pharmaceuticals recently announced that its Phase 3 NIMBLE trial evaluating cemdisiran monotherapy in adults with generalized myasthenia gravis met both primary and key secondary endpoints, marking a significant milestone for the company’s pipeline.
This advancement highlights Regeneron’s ongoing progress in rare disease therapeutics, underscoring the company’s commitment to expanding its portfolio of innovative treatments.
We’ll examine how these successful Phase 3 results for...